GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akcea Therapeutics Inc (NAS:AKCA) » Definitions » PB Ratio

Akcea Therapeutics (Akcea Therapeutics) PB Ratio : 3.85 (As of Apr. 25, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Akcea Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-25), Akcea Therapeutics's share price is $18.17. Akcea Therapeutics's Book Value per Share for the quarter that ended in Jun. 2020 was $4.72. Hence, Akcea Therapeutics's PB Ratio of today is 3.85.

The historical rank and industry rank for Akcea Therapeutics's PB Ratio or its related term are showing as below:

AKCA' s PB Ratio Range Over the Past 10 Years
Min: 2.24   Med: 6.38   Max: 14.72
Current: 3.65

During the past 6 years, Akcea Therapeutics's highest PB Ratio was 14.72. The lowest was 2.24. And the median was 6.38.

AKCA's PB Ratio is not ranked
in the Biotechnology industry.
Industry Median: 2.37 vs AKCA: 3.65

During the past 12 months, Akcea Therapeutics's average Book Value Per Share Growth Rate was 19.40% per year.

Back to Basics: PB Ratio


Akcea Therapeutics PB Ratio Historical Data

The historical data trend for Akcea Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akcea Therapeutics PB Ratio Chart

Akcea Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
PB Ratio
Get a 7-Day Free Trial - - 6.88 9.73 3.15

Akcea Therapeutics Quarterly Data
Dec14 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.91 4.44 3.15 2.84 2.90

Competitive Comparison of Akcea Therapeutics's PB Ratio

For the Biotechnology subindustry, Akcea Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akcea Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akcea Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Akcea Therapeutics's PB Ratio falls into.



Akcea Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Akcea Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Jun. 2020)
=18.17/4.719
=3.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Akcea Therapeutics  (NAS:AKCA) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Akcea Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Akcea Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Akcea Therapeutics (Akcea Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
22 Boston Wharf Road, 9th Floor, Boston, MA, USA, 02110
Akcea Therapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. It is advancing a mature pipeline of novel drugs with the potential to treat multiple diseases. The company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. Its most advanced drug, volanesorsen, has completed a Phase 3 clinical program for the treatment of familial chylomicronemia syndrome, or FCS, and is currently in Phase 3 clinical development for the treatment of familial partial lipodystrophy, or FPL.
Executives
Michael J. Yang director C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Joseph Iii Klein director C/O GENAISSANCE PHARMACEUTICALS INC, FIVE SCIENCE PARK, NEW HAVEN CT 06511
Sandford D Smith director C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
B Lynne Parshall director 2855 GAZELLE COURT, CARLSBAD CA 92010
Joshua F. Patterson officer: General Counsel C/O AKCEA THERAPEUTICS, INC., 22 BOSTON WHARF ROAD, 9TH FLOOR, BOSTON MA 02210
Damien Mcdevitt director, officer: Chief Executive Officer C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010
Alex G. Howarth officer: Chief Operating Officer C/O AKCEA THERAPEUTICS, INC., 22 BOSTON WHARF ROAD, 9TH FLOOR, BOSTON MA 02210
Kyle Jenne officer: Chief Commercial Officer C/O AKCEA THERAPEUTICS, INC. 22 BOSTON WHARF ROAD, 9TH FLOOR BOSTON MA 02210
William T. Andrews officer: Chief Medical Officer ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
Barbara Yanni director 1018 W. 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Michael Dennis Price officer: Chief Financial Officer
Elaine Hochberg director C/O AKCEA THERAPAEUTICS 55 CAMBRIDGE PKWY, STE 100 CAMBRIDGE MA 02142
Isis Pharmaceuticals Inc 10 percent owner 2855 GAZELLE COURT, CARLSBAD CA 92010
Michael F Maclean officer: Chief Financial Officer 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Paula Soteropoulos director, officer: Chief Executive Officer 49 WINONA STREET, PEABODY MA 01960

Akcea Therapeutics (Akcea Therapeutics) Headlines

From GuruFocus

Akcea Appoints Tracy Palmer Berns as Chief Compliance Officer

By PRNewswire PRNewswire 06-29-2020